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Abstract
Background: Preclinical imaging requires anaesthesia to reduce motion-related artefacts. For direct translational relevance,
anaesthesia must not significantly alter experimental outcome. This study reports on the effects of both anaesthetic and
carrier gas upon the uptake of [
64Cu]-CuATSM, [
99mTc]-HL91 and [
18F]-FMISO in a preclinical model of tumor hypoxia.
Methodology/Principal Findings: The effect of carrier gas and anaesthetic was studied in 6 groups of CaNT-bearing CBA
mice using [
64Cu]-CuATSM, [
99mTc]-HL91 or [
18F]-FMISO. Mice were anaesthetised with isoflurane in air, isoflurane in pure
oxygen, with ketamine/xylazine or hypnorm/hypnovel whilst breathing air, or in the awake state whilst breathing air or pure
oxygen. PET or SPECT imaging was performed after which the mice were killed for organ/tumor tracer quantitation. Tumor
hypoxia was confirmed. Arterial blood gas analysis was performed for the different anaesthetic regimes. The results
demonstrate marked influences on tumor uptake of both carrier gas and anaesthetic, and show differences between
[
99mTc]-HL91, [
18F]-FMISO and [
64Cu]-CuATSM. [
99mTc]-HL91 tumor uptake was only altered significantly by administration of
100% oxygen. The latter was not the case for [
18F]-FMISO and [
64Cu]-CuATSM. Tumor-to-muscle ratio (TMR) for both
compounds was reduced significantly when either oxygen or anaesthetics (isoflurane in air, ketamine/xylazine or hypnorm/
hypnovel) were introduced. For [
18F]-FMISO no further decrease was measured when both isoflurane and oxygen were
administered, [
64Cu]-CuATSM did show an additional significant decrease in TMR. When using the same anaesthetic
regimes, the extent of TMR reduction was less pronounced for [
64Cu]-CuATSM than for [
18F]-FMISO (40–60% versus 70%
reduction as compared to awake animals breathing air).
Conclusions/Significance: The use of anaesthesia can have profound effects on the experimental outcome. More
importantly, all tested anaesthetics reduced tumor-hypoxia uptake. Anaesthesia cannot be avoided in preclinical studies but
great care has to be taken in preclinical models of hypoxia as anaesthesia effects cannot be generalised across applications,
nor disease states.
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Introduction
Research into the hypoxic tumor microenvironment is acceler-
ating as the importance of tumor hypoxia becomes more and more
apparent. Most solid tumors develop regions of hypoxia as they
grow and evidence from experimental and clinical studies points to
a significant role for tumor hypoxia in tumor propagation,
resistance to radio- and chemotherapy and malignant progression
[1]. As the presence of tumor hypoxia represents a barrier for
effective cancer treatment, identifying patients whose tumors
contain hypoxic areas will therefore have an important role in
tumor prognosis, treatment and outcome.
The current gold standard to measure tissue oxygen concen-
tration, and thus tumor hypoxia, is the use of oxygen-sensitive
electrodes which determine the oxygen partial pressure pO2 [2].
However, sampling errors are easily introduced and given the
invasive nature of the method, it is difficult to reach deep-seated
tumors. An elegant alternative could be presented by using nuclear
imaging techniques.
Over the years, imaging as a noninvasive method has attracted
a lot of attention and several radiotracers have been developed for
the evaluation of hypoxia using Positron Emission Tomography
(PET) and Single Photon Emission Computed Tomography
(SPECT). Examples of such compounds include the nitroimida-
zoles such as [
18F]fluoromisonidazole ([
18F]-FMISO) and [
123I]io-
doazomycin arabinoside (IAZA) and non-nitroimidazole com-
pounds such as [
64Cu]diacetyl-bis(N4-methylthiosemicarbazone)
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e25911([
64Cu]-CuATSM) and [
99mTc]butylene amineoxime ([
99mTc]-
HL91) [3]. To date, more and more candidates are being
developed to improve hypoxia targeting characteristics. However,
a direct comparison of compounds is often difficult mainly due to a
wide variety in experimental set ups, an important component of
which is the anaesthetic protocol.
While anaesthesia is preferred in preclinical imaging studies to
reduce subject movement, anaesthetic agents, and their carrier
gasses in case of volatile anaesthetics, can influence radiotracer
biodistribution and tumor uptake substantially. This is well known
for neurological applications and many reports describe the effect
of anaesthetics, mostly barbiturates, on brain function [4,5,6].
However, less is published on the general impact of anaesthesia on
extracerebral metabolism, especially in nuclear medicine applica-
tions. Zanelli et al described the influence of pentobarbital on
blood perfusion in transplanted mouse tumors. Using
86Rb,
125I-
human serum albumin and
51Cr-labeled red blood cells,
pentobarbital was found to both increase the relative blood
perfusion in tumors and kidneys and to decrease the relative
muscle perfusion, but to reduce the blood volume of the tumor and
kidneys [7]. It was only in 2005 that Lee et al. studied the effect of
ketamine/xylazine and pentobarbital on the biodistribution and
tumor uptake of the most abundantly used tracer in nuclear
medicine: [
18F]-Fluorodeoxyglucose ([
18F]-FDG) [8]. Both keta-
mine/xylazine and pentobarbital sedation increased blood [
18F]-
FDG activity resulting in decreased tumor to muscle ratios and
PET image contrast. A few years later, these findings were
extended for isoflurane and sevoflurane in both air and oxygen by
Flores and co-workers who demonstrated that both the anaesthetic
drug and the carrier gas can influence [
18F]-FDG tumor uptake
[9].
As both organ perfusion and function are often changed by
anaesthesia, it seems obvious to test its effects on tumor hypoxia as
well. Although the effects of anaesthetics on in vivo oxygen
electrode measurements have been examined, so far no papers
have considered its effects on radiodiagnostic markers [10].
Moreover, no consensus for the optimal anaesthetic protocol
exists for preclinical hypoxia imaging using agents such as
[
99mTc]-HL91, [
64Cu]-CuATSM or [
18F]-FMISO, albeit an
Investigational New Drug Applications (IND) was filed for the
latter one. Although the anaesthesia method is kept constant
throughout each study, different studies use different protocols
which differ in the anaesthetic drugs used (isoflurane versus
pentobarbital and ketamine/xylazine), and in the carrier gases
(oxygen, air or a mixture) and the administration routes
(inhalation, i.p. or i.m.). The huge amount of existing data on
hypoxia imaging, together with the filed IND for [
18F]-FMISO
point out the importance of standardizing preclinical hypoxia
imaging regimes across studies.
This report describes for the first time the impact of the
anaesthetic protocol on [
18F]-FMISO, [
64Cu]-CuATSM and
[
99mTc]-HL91 uptake in hypoxic tumors for imaging applications
using PET or SPECT.
Materials and Methods
Ethics Statement
All animal studies were performed in accordance with the
Animals Scientific Procedures Act of 1986 (UK) (Project License
Number 30/2514 issued by the Home Office).
Radiopharmaceuticals. [
18F]-FMISO (specific activity=
115 GBq/mmol) was obtained from the Wolfson Brain Imaging
Centre, Addenbrookes Hospital, Cambridge.
[
99mTc]-HL91 was prepared as follows. HL91 solution (28 mL,
2 mg/mL), tartrate solution (20 mL, 10 mg/mL; Sigma-Aldrich)
and sodium carbonate buffer solution (100 mL, pH 10.0, 0.1 mol/
L; Sigma-Aldrich) were mixed, immediately followed by the
addition of [
99mTcO4]
2 (100–150 MBq) and freshly prepared
SnCl2 solution (25 mL, 1 mg/mL in 1 M HCl; Sigma-Aldrich).
This mixture was incubated for 30 min at room temperature.
Thereafter, 50% acetonitrile aqueous solution was used to
determine [
99mTc]-colloid on Whatman No.1 paper strip
(Rf=0; Rf [
99mTc]-HL91=1) and water to determine pertechne-
tate (Rf=1.0; Rf [
99mTc]-HL91=0). The radiochemical yield for
[
99mTc]-HL91 was 96%67% and no further purification was
needed which resulted in a specific activity of 3.5–5 MBq/mg.
Copper-64 was purchased from the Wolfson Brain Imaging
Centre, Addenbrookes Hospital, Cambridge or from the PET
Imaging Centre, St Thomas’ Hospital, London, UK. [
64Cu]-
CuATSM was prepared from H2ATSM as previously described
[11]. Briefly, to 40 mLo fH 2ATSM stock solution (1 mg/mL) was
added 50 mL of dimethyl sulfoxide (DMSO) and 50 mL of aqueous
[
64Cu]Cu(OAc)2 (100 MBq). This was loaded onto a C-18 Sep-
Pak LightH, pre-equilibrated with 2 mL ethanol (EtOH) and
10 mL H2O. After loading the sample, 5 mL H2O was passed
through to remove the DMSO and any unreacted Copper-64.
The labelled complex was eluted in EtOH (600 mL, following a
200 mL void volume). The EtOH was concentrated under a
stream of nitrogen and diluted with 0.9% saline solution to give a
,10% EtOH solution for injection. [
64Cu]-CuATSM was
prepared in 90% isolated radiochemical yield, the radiochemical
purity was .98% as determined by radio-TLC on silica gel plates
using ethyl acetate/methanol (95:5) as the mobile phase. The
specific activity of the administered radiopharmaceutical was 2–
3 MBq/mg of labelling precursor.
Animal model. Water and food were freely available during
the experimental period. The murine adenocarcinoma NT
(CaNT) was implanted subcutaneously onto the right thigh of 6–
7 week-old female CBA mice. Fifty mL of a crude cell suspension,
prepared by mechanical dissociation of an excised tumor from a
donor animal, was injected. Tumors were selected for imaging
when the geometric mean diameter reached 6–8 mm,
approximately 3 weeks after implantation. Throughout the
experiments, mice were maintained at 37uC and respiration rate
was monitored (60–90 respirations/minute for imaging and 30–60
respirations/minute for blood gas analysis).
Anaesthesia and experimental set-up. For [
18F]-FMISO,
[
64Cu]-CuATSM and [
99mTc]-HL91, the effects of anaesthesia on
tumor uptake and biodistribution were studied in 6 groups (4
groups for [
64Cu]-CuATSM) of CaNT bearing CBA mice (n=9
per group). Anaesthesia was induced and maintained using either
gases (isoflurane in oxygen (IO) or in room-air (IA)), or injectable
agents (hypnorm/hypnovel (HHA) or Ketamine/Xylazine (KXA),
both breathing room air). Non-anaesthetised mice were kept in
room air (UA) or in a 100% oxygen atmosphere (UO). An
overview of the protocols used is presented in Table 1. PET or
planar SPECT imaging was performed for 2 h on all anaesthetised
mice following injection of the radiolabeled compound.
At 2 hours p.i., all mice from all anaesthetic regimes (IO, IA,
HHA, KXA, UO and UA) were sacrificed by cervical dislocation.
The organs and tissues were removed, washed and weighed. The
blood was collected and weighed. The tumor was collected,
weighed and flash frozen. The radioactivity of all samples was
counted by use of an automated gamma-counting system (Perkin
Elmer). The amount of radioactivity in the organs and tissues was
decay corrected and calculated as % injected dose per gram
(%ID/g): [(activitytissue)/(weighttissue6activityinjected)].
Effect of Anesthesia on Hypoxia Imaging
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PET/CT. PET imaging was performed using the Inveon
PET/CT system (Siemens Preclinical Solutions) equipped with a
custom built imaging cradle. Computed Tomography (CT) based
attenuation correction was performed before each PET emission
scan and was also used for anatomical referencing. Two hour
whole-body dynamic scans were acquired. Anaesthesia was
induced, mice were placed supine, head first, in the imaging
cradle and a cannula (30-gauge needle attached to PE-10 tubing)
was inserted into the lateral tail vein. Following the attenuation
CT-scan, 10 MBq of [
18F]-FMISO or [
64Cu]-CuATSM was
injected through the cannula immediately after the PET emission
data acquisition was initiated. Data were histogrammed in 21 time
frames (6615s, 3660s, 56300s, 36600s and 46900s) and global
deadtime correction and Fourier rebinning were applied. The
dynamic histograms were reconstructed using a 2-dimensional
filtered backprojection algorithm, a Ramp projection filter, a 0.5/
mm Nyquist projection cut-off value, no zoom and a matrix size
of 12861286159 (sagittal6coronal6transversal). ROI image
analysis was performed using the Inveon Research Workplace
software (IRW, version 2.2, Siemens Preclinical Solutions).
SPECT. Planar SPECT imaging was performed using the
nanoSPECT/CT system (Bioscan) equipped with an Ultra High
Resolution (UHR) parallel hole collimator. Anaesthesia was
induced, 4 mice were placed simultaneously, supine, head first,
on the collimator and a cannula was inserted into their lateral tail
vein. Ten MBq of [
99mTc]-HL91 was injected through the
cannula immediately after the two hour whole-body dynamic
scans were initiated. Fifty-five time frames (30620s, 10660s, 106
300s and 56 600s) were acquired. ROI image analysis was
performed using ImageJ [12].
Blood gas analysis. Non-tumor bearing CBA mice (n=5
per anaesthetic regime) were anaesthetised using the different
anaesthesia regimes (IO, IA, HHA and KXA). Femoral
cannulation (PE10 tubing) was performed to allow for arterial
blood gas analysis. A blood sample (50 ml) was collected at 90 min
post anaesthesia induction and pO2, pCO2 and sO2 was
determined using an I-Stat blood gas analyser (Model 300,
Abbott).
Tumor hypoxia. The hypoxic status of all tumors was
confirmed using the OxyLite probe (Oxford Optronix Ltd),
which provided continuous real-time tissue pO2 measurements at
the centre of the tumor. Immunohistological staining for EF5 (2-(2-
nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide;
University of Pennsylvania) as described by Lee J et al was
performed on a subset of tumors [13]. For EF5 studies, tumor
bearing mice from each anaesthetic group (n=3) were
administered 200 ml of 10 mM EF5 in 0.9% saline i.v. 3 h prior
to tumor excision (EF5 was obtained from Dr. Cameron Koch,
University of Pennsylvania, Philadelphia, PA). Sections were
stored in 1% paraformaldehyde at 4uC and images were
acquired within 2 days of staining. Fluorescence detection was
performed at610 magnification with an upright motorised Nikon
Eclipse 90i system (Nikon, UK), fitted with a motorised stage and
equipped with cooled charge-coupled Hamamatsu ORCA-ER
camera and acquisition software.
Statistical analysis. Tumor uptake of [
18F]-FMISO, [
64Cu]-
CuATSM or [
99mTc]-HL91 in vivo was compared for different
anaesthesia groups by 1-way parametric ANOVA using the Tukey
adjustment for multiple comparisons (P,0.05). Correlations
between biodistribution and imaging results were made using a
Pearson correlation test (P,0.05). All other statistical comparisons
were made using a Student t test (P,0.05).
Results
Planar SPECT imaging using a UHR collimator allowed for
very fast 2D imaging, resulting in images with acceptable
resolution (2.0 mm, tested in-house). Although one spatial
dimension was lost and CT was not possible, temporal resolution
was gained and thus kinetic analysis of [
99mTc]-HL91, the most
studied radiotracer for hypoxia imaging using SPECT, was
performed. Four mice were imaged simultaneously using the
anaesthesia protocols as described in Table 1 and a representative
planar SPECT image for each condition at 2 h p.i. is shown in
Figure 1. The resulting biodistribution kinetics for tumor and the
tumor-to-muscle ratios (TMR) are presented in Figure 2 and 3,
respectively. More detailed dissection analysis was performed
when steady state for [
99mTc]-HL91 tumor uptake was reached at
2 h p.i. and these results, expressed as %ID/g for each organ, are
shown in Table 2. Comparable TMR were obtained for awake
animals breathing air and for those anaesthetised with isoflurane
in air or hypnorm/hypnovel. However, when additional oxygen
was introduced to the system, either for awake or anaesthetised
Table 1. Schematic representation of the anaesthesia regimes used.
Group Anaesthesia induction Anaesthesia maintenance
IO* 3% isoflurane in 100% oxygen 1.5% isoflurane in 100% oxygen
IA{ 3% isoflurane in room air 1.5% isoflurane in room air
HHA{ Hypnorm/H2O/Hypnovel
1:2:1 at 10 ml/kg (i.p.)
Hypnorm/H2O/Hypnovel
1:2:1 at 0.3 ml/kg (i.p.)
KXA1 Ketamine/Xylazine
80 mg/kg : 10 mg/kg (i.p.)
Ketamine/Xylazine
8 mg/kg : 1 mg/kg (i.p.)
UOI Not applicable: no imaging performed, only dissection.
100% oxygen atmosphere during radiotracer distribution
UA" Not applicable: no imaging performed, only dissection.
room air atmosphere during radiotracer distribution
*Anaesthetised using Isoflurane in Oxygen;
{Anaesthetised using Isoflurane in room air;
{Anaesthetised using Hypnorm/Hypnovel;
1Anaesthetised using Ketamine/Xylazine;
IAwake breathing oxygen;
"Awake breathing room air.
doi:10.1371/journal.pone.0025911.t001
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same was true when a ketamine/xylazine mixture was used. No
substantial changes in TMR were detected when only isoflurane,
and not oxygen, was supplied. The effects of anaesthesia on the
tumor-to-blood ratio (TBR) showed a different pattern, namely:
IO=UO,UA=IA,KXA=HHA. In other words, the TBRs for
both injectable anaesthetics were highest whereas those for oxygen
as a carrier gas were lowest and the latter regardless of the use of
isoflurane.
Nevertheless, most hypoxia imaging agents are not being
developed for SPECT but for PET [3]. The latter technique
benefits from list-mode data acquisition resulting in high temporal
resolution with full 3D spatial resolution. To date, [
18F]-FMISO
and [
64Cu]-CuATSM are the lead contenders for in vivo
assessment of hypoxia in humans [14,15]. As these compounds
belong to two distinct classes: the nitroimidazoles and the
bis(thiosemicarbazonates), and exploit different tumor localisation
mechanisms, it was important to include both in this study [16].
Representative PET images for [
18F]-FMISO and [
64Cu]-
CuATSM for each condition are depicted in Figures 4 and 5,
respectively. The blood input function and dynamic tumor uptake
of [
18F]-FMISO and [
64Cu]-CuATSM as a function of time is
illustrated in Figures 6A, 6B, 7A and 7B. The resulting TMRs are
presented in Figure 8 and 9, including those for the awake state.
Dissection results for each organ at 2 h p.i. are shown in Tables 3
and 4. The TMR for both compounds was reduced significantly
when only oxygen or any anaesthetic were used as compared to
awake mice breathing air (p,0.001). However, more subtle
differences exist for [
64Cu]-CuATSM. Indeed, the effects of
isoflurane or oxygen alone could not be distinguished from each
other when using [
18F]-FMISO as a tumor hypoxia imaging agent.
Yet for [
64Cu]-CuATSM, the TMR was reduced when oxygen
was added to the breathing mixture, but even more so when
isoflurane was supplemented. Again, the results for TBR diverge
slightly from those for TMR for both [
18F]-FMISO and [
64Cu]-
CuATSM, and show a different pattern as compared to [
99mTc]-
HL91. Briefly, TBR could be ranked as follows: IO=IA,UO=
KXA=HHA,UA.
Although the CaNT bearing CBA mouse model is very robust
in terms of tumor growth and tumor hypoxia status throughout
tumor development, the presence and level of hypoxia was
confirmed before mice entered the study using OxyLite measure-
ments (average pO2 for mouse population: 2.3 mmHg6
0.9 mmHg) . Following imaging and prior to culling the mice
Figure 1. Representative planar SPECT images of the uptake of
[
99mTc]-HL91 in CaNT bearing CBA mice at steady state (2 h
p.i.). The tumour is indicated by the white arrow. (A) IA:
Anaesthetised using Isoflurane in room air; (B) IO: Anaesthetised using
Isoflurane in Oxygen; (C) HHA: Anaesthetised using Hypnorm/Hypnovel;
(D) KXA: Anaesthetised using Ketamine/Xylazine.
doi:10.1371/journal.pone.0025911.g001
Figure 2. Overall mean tumor uptake for [
99mTc]-HL91 as a function of time by dynamic planar SPECT imaging. HHA: Anaesthetised
using Hypnorm/Hypnovel; IA: Anaesthetised using Isoflurane in room air; IO: Anaesthetised using Isoflurane in Oxygen; KXA: Anaesthetised using
Ketamine/Xylazine.
doi:10.1371/journal.pone.0025911.g002
Figure 3. Tumor-to-muscle ratio for [
99mTc]-HL91 for all tested
anaesthetic regimes. HHA: Anaesthetised using Hypnorm/Hypnovel;
IA: Anaesthetised using Isoflurane in room air; IO: Anaesthetised using
Isoflurane in Oxygen; KXA: Anaesthetised using Ketamine/Xylazine;
TMR: tumor-to-muscle ratio; UA: Awake breathing room air; UO: Awake
breathing oxygen.
doi:10.1371/journal.pone.0025911.g003
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The latter resulted in average tumor pO2 values for IO, IA, HHA,
KXA, UA and UO of 1.5 mmHg60.4 mmHg, 1.9 mmHg6
0.6 mmHg, 1.4 mmHg60.5 mmHg, 2.4 mmHg60.4 mmHg,
0.9 mmHg60.3 mmHg and 1.1 mmHg60.3 mmHg. No signifi-
cant differences were observed for the different anaesthesia
regimes. Additionally, immunohistological EF5 staining on tumors
from each anaesthetic group showed no differences in the extent of
hypoxia for IA, HHA, KXA and UA. However, when oxygen was
used as a carrier gas (IO and UO) the latter was largely reduced.
As variations in arterial oxygen concentrations can lead to acute
hypoxia, it is important to check the arterial pO2, pCO2 and blood
oxygen saturation levels (sO2). Arterial blood sampling was
performed and the results summarised in Table 5. No significant
differences could be detected for sO2 and pCO2 for the different
anaesthesia regimes. However, pO2 was significantly higher only
when isoflurane in 100% oxygen was used. Measurements could
not be performed for the UO and UA groups due to the necessary
surgical intervention.
Discussion
Tissue hypoxia is studied in many medical disciplines as it is a
prognostic marker associated with an aggressive clinical and
biological phenotype [17]. However, despite its occurrence in
other pathologic conditions, including myocardial ischemia and
stroke, hypoxia imaging is much more advanced in oncology
Table 2. Biodistribution results for [
99mTc]-HL91 at 2 h p.i. in a
CaNT bearing CBA mouse model.
IO* IA{ HHA{ KXA1 UAI UO"
Blood 2.460.1 5.760.9 3.760.5 3.660.3 2.460.6 2.760.2
Tumor 1.360.1 2.660.5 3.960.7 4.360.1 2.260.5 1.260.0
Muscle 0.560.1 0.760.1 0.960.3 0.960.1 0.460.1 0.460.0
Skin 1.160.4 1.160.3 1.560.1 1.860.4 0.860.4 0.960.2
Stomach 1.560.4 3.460.8 19.6612.4 14.464.5 4.162.4 3.260.4
Small
intestine
17.663.1 10.263.6 21.8614.9 7.761.1 2.761.1 3.260.4
Large
intestine
3.961.9 4.860.7 11.060.9 5.161.3 14.463.2 12.061.8
Fat 0.960.6 1.860.5 2.560.2 2.760.5 0.760.1 0.660.1
Spleen 2.260.7 2.060.4 7.660.8 10.062.1 6.261.5 4.960.6
Liver 9.961.6 9.561.6 9.660.8 7.861.3 10.763.4 12.761.7
Kidneys 7.864.9 9.162.4 9.864.1 7.762.1 5.161.1 6.760.8
Heart 1.160.1 2.160.4 1.9960.3 2.060.7 0.960.1 1.160.1
Lungs 1.760.2 4.560.7 4.160.7 2.660.5 1.960.4 1.560.1
TMR 2.460.6 4.660.7 4.760.5 3.660.5 4.860.8 3.060.1
TBR 0.560.1 0.860.3 1.260.2 1.360.3 0.960.2 0.460.1
Results are expressed as average % injected dose per gram tissue 6 standard
deviation. TMR=ratio tumor-to-muscle, TBR=ratio tumor-to-blood.
*Anaesthetised using Isoflurane in Oxygen;
{Anaesthetised using Isoflurane in room air;
{Anaesthetised using Hypnorm/Hypnovel;
1Anaesthetised using Ketamine/Xylazine;
IAwake breathing room air;
"Awake breathing oxygen.
doi:10.1371/journal.pone.0025911.t002
Figure 4. Representative PET/CT images of the uptake of [
18F]-
FMISO in CaNT bearing CBA mice at steady state (2 h p.i.). (A)
IA: Anaesthetised using Isoflurane in room air; (B) IO: Anaesthetised
using Isoflurane in Oxygen; (C) HHA: Anaesthetised using Hypnorm/
Hypnovel; (D) KXA: Anaesthetised using Ketamine/Xylazine. T=tumour,
B=bladder, L=Liver.
doi:10.1371/journal.pone.0025911.g004
Figure 5. Representative PET/CT images of the uptake of
[
64Cu]-CuATSM in CaNT bearing CBA mice at steady state (2 h
p.i.). (A) IA: Anaesthetised using Isoflurane in room air; (B) IO:
Anaesthetised using Isoflurane in Oxygen.
doi:10.1371/journal.pone.0025911.g005
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assess overall prognosis. In order to provide a priori information on
tumor hypoxia, the oxygenation status of solid tumors has been
evaluated extensively using a wide variety of both invasive and
non-invasive techniques [18,19]. However, non-invasive tech-
niques that permit both serial imaging and the detection of tumor
hypoxia levels could provide valuable information on disease status
and on treatment response. As a result, the search for a non-
invasive hypoxia assay has been continuous and various PET and
SPECT compounds have been developed and are being evaluated
in vivo in small animal models [3]. While anaesthesia is preferred
in preclinical imaging studies to reduce motion artefacts,
anaesthetic agents, and their carrier gases, in the case of volatile
anaesthetics, have the potential to alter the study outcome
dramatically. Therefore, it is important to study the effects of
anaesthesia and come to a consensus imaging protocol before
embarking on a programme of in vivo experiments.
In this study, the CaNT bearing CBA mouse model was used
and 2 different methods were applied to confirm the tumor
hypoxic status, i.e. immunohistological EF5 staining and pO2
OxyLite measurement. Both techniques showed the presence of
tumor hypoxia throughout tumor development (data not shown).
Although the pO2 measurements were limited in sample size, it
was a simple and fast method to get a good estimate of the hypoxia
status of the tumors, i.e. is hypoxia present or not. As well as
considering the effects of the anaesthetic, the imaging set-up needs
validation to avoid introducing other biases. Changes in core
temperature have the potential to alter various physiological
factors including blood perfusion, pO2, vascular permeability and
intratumoral pressure. Furthermore, mild hyperthermia improves
tumor oxygenation in rodents [20]. For these reasons, all animals
were placed on a heating pad and a negative feedback loop
connected to a rectal probe used to ensure a stable core
temperature of 37uC.
Having validated our experimental set-up, the effects of
anaesthesia could be studied in detail. The results presented in
this study not only established the marked influences on tumor
uptake of both carrier gas and anaesthetic, but also demonstrated
pronounced differences between [
99mTc]-HL91, [
18F]-FMISO
and [
64Cu]-CuATSM despite the fact they are all designed to
target hypoxia specifically. Thus the effects of isoflurane and
hypnorm/hypnovel on the TMR were not significant for [
99mTc]-
HL91 whilst the impact of ketamine/xylazine use was less
pronounced compared to [
18F]-FMISO and [
64Cu]-CuATSM.
By and large, [
99mTc]-HL91 tumor uptake could only be altered
significantly by administration of 100% oxygen. The latter was
certainly not the case for [
18F]-FMISO and [
64Cu]-CuATSM.
The TMR for both compounds was reduced significantly when
either oxygen or anaesthetics (isoflurane in air, ketamine/xylazine
or hypnorm/hypnovel) were introduced. Whilst for [
18F]-FMISO
Figure 6. Overall mean heart and tumor uptake for [
18F]-FMISO as a function of time by kinetic PET imaging. (A) Heart and (B) Tumour
uptake. HHA: Anaesthetised using Hypnorm/Hypnovel; IA: Anaesthetised using Isoflurane in room air; IO: Anaesthetised using Isoflurane in Oxygen;
KXA: Anaesthetised using Ketamine/Xylazine.
doi:10.1371/journal.pone.0025911.g006
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oxygen were administered, [
64Cu]-CuATSM did show an
additional, subtle but significant, decrease in TMR. Moreover,
when using the same anaesthetic regimes, the extent of TMR
reduction was less pronounced for [
64Cu]-CuATSM than for
[
18F]-FMISO (40–60% versus 70%, respectively). These differ-
ences in tracer behaviour might be an indication of their different
hypoxia targeting mechanisms and/or hypoxia selectivity, a
hypothesis that is also supported by the differences in TBR.
Although the effects of anaesthesia are not as pronounced and
universal for TBR as compared to TMR, they drop significantly
for both [
64Cu]-CuATSM and [
18F]-FMISO when either oxygen
Figure 7. Overall mean heart and tumor uptake for [
64Cu]-CuATSM as a function of time by kinetic PET imaging. (A) Heart and (B)
Tumour uptake. IA: Anaesthetised using Isoflurane in room air; IO: Anaesthetised using Isoflurane in Oxygen.
doi:10.1371/journal.pone.0025911.g007
Figure 8. Tumor-to-muscle ratio for [
18F]-FMISO for all tested
anaesthetic regimes. HHA: Anaesthetised using Hypnorm/Hypnovel;
IA: Anaesthetised using Isoflurane in room air; IO: Anaesthetised using
Isoflurane in Oxygen; KXA: Anaesthetised using Ketamine/Xylazine;
TMR: tumor-to-muscle ratio; UA: Awake breathing room air; UO: Awake
breathing oxygen.
doi:10.1371/journal.pone.0025911.g008
Figure 9. Tumor-to-muscle ratio for [
64Cu]-CuATSM for all
tested anaesthetic regimes. IA: Anaesthetised using Isoflurane in
room air; IO: Anaesthetised using Isoflurane in Oxygen; TMR: tumor-to-
muscle ratio; UA: Awake breathing room air; UO: Awake breathing
oxygen.
doi:10.1371/journal.pone.0025911.g009
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isoflurane was administered. Again, [
99mTc]-HL91 behaves
differently. Both injectable anaesthetic regimes KXA and HHA
raised the TBR as compared to awake mice breathing room air,
whereas isoflurane did not seem to have any effect. Actually, only
the use of oxygen reduced the TBRs. Despite the fact that the
hypoxia targeting mechanism for [
99mTc]-HL91 is not yet known,
these results might be another indication that passive diffusion is
not the major pathway as was already suggested by Hsia et al [21].
To date, it is well established in small animal models, that
radiation response can be improved and tumor hypoxia decreased
by normobaric oxygen or carbogen breathing [22,23]. Robinson
SP et al reported that carbogen and 100% oxygen significantly
increased arterial pO2, whilst only carbogen significantly increased
arterial pCO2 and this without changing the arterial blood
pressure. Additionally, they and others indicated that breathing
high-oxygen content gases results in little additional O2 transport
capacity as the haemoglobin is already almost completely
saturated under air breathing conditions [24,25]. Our results are
congruent with the latter studies as only isoflurane in air but not
the other anaesthetics caused an increase in arterial pO2, whilst
pCO2 and sO2 remained constant for all tested regimes. This
elevated arterial pO2 might relate to the reduced tumor hypoxia
extent as measured by EF5 staining. Indeed, this could be backed
up by others who either demonstrated a direct relationship
between the extent of EF5 staining and tissue oxygenation status
or confirmed an increase in tumor pO2 after 100% oxygen
breathing [26,27,28]. Although corroborated by EF5 staining,
OxyLite electrode measurements post imaging did not show the
increased tumor oxygenation status when mice were breathing
100% oxygen. This could be attributed to the introduction of
sampling errors as only a single measurement, and not pO2
histography, was performed due to the small size of murine
tumors. Nonetheless, taken together all the above observations
vindicate the lower TMR values for all three radiopharmaceuticals
when oxygen was used as a carrier gas. Indeed, once [
18F]-FMISO
has entered the cell freely through passive diffusion, its specific
retention in hypoxic tissues is dependent on the local oxygen
tension [15]. Although the precise mechanistic details and the pO2
dependence for [
64Cu]-CuATSM remains uncertain, the accepted
mechanistic scheme as it stands today also involves bioreduction
and trapping [29].
Although Lewis et al reported similar results to those presented
here, i.e. that for animals breathing 100% oxygen, tumor uptake
was 48% less than for those breathing air, others such as
Table 3. Biodistribution results for [
18F]-FMISO at 2 h p.i. in a
CaNT bearing CBA mouse model.
IO* IA{ HHA{ KXA1 UAI UO"
Blood 2.760.4 2.360.2 1.760.2 1.860.2 1.260.1 1.360.2
Tumor 4.560.4 3.960.4 7.460.9 5.760.7 6.560.7 4.160.5
Muscle 2.760.3 1.960.3 1.460.1 1.660.1 1.260.1 2.560.2
Skin 0.660.1 0.660.0 0.760.1 0.660.1 0.660.0 0.660.1
Stomach 1.660.7 2.860.4 2.260.7 2.760.4 2.260.3 1.460.2
Small
intestine
6.560.3 3.960.4 5.461.1 7.060.6 5.961.7 2.760.2
Large
intestine
14.161.8 9.460.9 19.062.3 14.563.1 15.362.7 21.062.2
Fat 0.760.0 0.760.1 0.660.1 0.660.1 0.860.1 1.460.3
Spleen 2.360.2 2.460.2 1.560.3 1.960.1 1.460.1 1.960.2
Liver 3.960.5 2.760.3 3.560.4 9.261.0 3.860.7 2.660.2
Kidneys 4.060.5 3.760.3 2.960.1 3.660.4 2.560.3 2.160.2
Heart 3.760.4 3.660.4 2.560.2 2.260.2 1.660.2 2.960.3
Lungs 2.560.4 3.060.6 2.260.2 2.060.2 1.960.2 2.160.2
TMR 1.760.2 2.260.4 5.260.7 3.560.7 5.360.6 1.760.2
TBR 1.760.2 1.860.3 4.060.9 3.360.2 5.660.6 3.060.4
Results are expressed as average % injected dose per gram tissue 6 standard
deviation. TMR=ratio tumor-to-muscle, TBR=ratio tumor-to-blood.
*Anaesthetised using Isoflurane in Oxygen;
{Anaesthetised using Isoflurane in room air;
{Anaesthetised using Hypnorm/Hypnovel;
1Anaesthetised using Ketamine/Xylazine;
IAwake breathing room air;
"Awake breathing oxygen.
doi:10.1371/journal.pone.0025911.t003
Table 4. Biodistribution results for [
64Cu]-CuATSM at 2 h p.i.
in a CaNT bearing CBA mouse model.
IO* IA{ UA{ UO1
Blood 0.960.1 0.860.1 1.260.0 1.260.1
Tumor 1.160.1 1.460.0 3.160.3 2.360.0
Muscle 0.360.0 0.360.0 0.460.0 0.560.1
Skin 0.460.0 0.560.0 0.460.0 0.460.0
Stomach 6.161.0 4.760.5 3.960.6 6.060.7
Small intestine 9.960.5 9.760.3 4.760.6 9.960.2
Large intestine 3.360.3 3.760.3 11.961.1 5.660.1
Fat 0.560.0 0.560.1 0.460.1 0.560.1
Spleen 1.760.1 1.760.1 1.560.2 1.660.1
Liver 11.760.8 10.660.3 6.860.3 6.960.8
Kidneys 5.960.5 6.260.8 4.860.2 5.060.5
Heart 1.560.2 1.360.1 2.160.1 2.360.2
Lungs 5.260.3 5.860.4 5.860.5 4.660.3
TMR 3.660.2 4.060.3 8.261.3 4.860.6
TBR 1.260.2 1.860.1 2.660.4 1.960.1
Results are expressed as average % injected dose per gram tissue 6 standard
deviation. TMR=ratio tumor-to-muscle, TBR=ratio tumor-to-blood.
*Anaesthetised using Isoflurane in Oxygen;
{Anaesthetised using Isoflurane in room air;
{Awake breathing room air;
1Awake breathing oxygen.
doi:10.1371/journal.pone.0025911.t004
Table 5. Arterial pO2, pCO2 and sO2 levels at 90 min post
anaesthesia induction for different anaesthesia regimes (n=5/
group).
Group pO2 (mmHg) pCO2 (mmHg) sO2 (%)
IO* 434668 60.260.4 10060
IA{ 103613 58.266.0 9861
HHA{ 95676 0 . 6 68.1 9464
KXA1 94646 0 . 6 61.5 9563
Results are expressed as average 6 standard deviation.
*Anaesthetised using Isoflurane in Oxygen;
{Anaesthetised using Isoflurane in room air;
{Anaesthetised using Hypnorm/Hypnovel;
1Anaesthetised using Ketamine/Xylazine.
doi:10.1371/journal.pone.0025911.t005
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64Cu]-CuATSM
tumor uptake was not decreased after carbogen breathing
[30,31,32]. Fortuitously, these discrepancies are not necessarily
due to a lack of hypoxia selectivity of the tested radiotracers but
could be attributed to the use of carbogen [25,33,34].
Apart from the effects of the inspired gases, the anaesthetic
drugs themselves also reduced the TMR values for [
18F]-FMISO
and [
64Cu]-CuATSM. Moreover, these changes reflect a differ-
ence in uptake and not in contrast agent delivery as the dynamic
blood curves showed no alterations for the tested anaesthesia
regimes. Although the precise cause of these results was not the
focus of this paper, they are not surprising. Indeed, among other
parameters, variation in blood flow values alone may be
responsible for altering the hypoxic cell fraction of experimental
rodent tumors. Lee et al reported that Xylazine not only induces a
strong hyperglycemic effect resulting in elevated plasma glucose
levels but also causes a diuretic and natriuretic response [8].
Moreover, Menke et al showed that tumor blood flow in
Ketamine/Xylazine sedated rats was reduced as compared to
conscious animals [35]. While inhalational anaesthetics are much
easier and safer to use, they do have the potential to influence
hypoxia imaging results. Halogenated anaesthetics not only alter
tumor metabolism and cardiovascular parameters, leading to
hypercapnia, acidosis, reduced cardiac function, but they also
reduce tumor pH and blood glucose levels [36,37].
In conclusion, we focussed our study on oncology and more
precisely on the preclinical development of radiotracers for non-
invasive hypoxia imaging because of the heterogeneous and
dynamic nature of hypoxia in tumors. However, the results could
be applied to other disciplines and may be significant in the wider
preclinical and clinical worlds. Our data showed that the use of
anaesthesia can have profound effects on the experimental
outcome. More importantly, all tested anaesthetics significantly
reduced tumor-hypoxia uptake. Thus, the detectable differences
between hypoxic and non-hypoxic tissue will be smaller under
such anaesthesia leading to a reduction in statistical power and an
increase in animal use to achieve good discrimination. Maximum
tumor uptake was observed for conscious animals and as a result
hypoxia imaging should employ conscious tracer uptake combined
with anaesthesia only for the scan itself. This will not only benefit
the experimental outcome but it will also better reflect the clinical
situation as protocols could be more easily translated into the
clinic. However, more often than not, anaesthesia cannot be
avoided in preclinical studies but great care has to be taken in
preclinical models of hypoxia as anaesthesia effects cannot be
generalised across applications, let alone diseases. The presence of
these anaesthesia related biological effects implies in practice that
investigators should perform additional studies when the use of
anaesthetics is required in order to characterize or rule out its
confounding effects.
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